Reach Us +1-504-608-2390
Revisit Rescula and Cystoid Macular Edema and Refractory Glaucoma | OMICS International | Abstract
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Review Article

Revisit Rescula and Cystoid Macular Edema and Refractory Glaucoma

Tina Guanting Qiu* (Review by E. Randy Craven MD, Martin Wand MD, Bruce Shields MD)
Biopharma Physician Consultant (independent), Peabody, MA, USA
Corresponding Author : Tina Guanting Qiu, MD PhD
Biopharma Physician Consultant (independent)
Peabody, MA United States
Tel: 001-978 998 0624
E-mail: [email protected]
Received: August 06, 2015 Accepted: September 09, 2015 Published: September 13, 2015
Citation: Qiu TG (2015) Revisit Rescula and Cystoid Macular Edema and Refractory Glaucoma. J Clin Exp Ophthalmol 6:473. doi:10.4172/2155-9570.1000473
Copyright: © 2015 Qiu TG et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Scholar Google


Rescula (unoprostone isopropyl) has been in the market as ocular hypotensive drug since 1994. There are amounting scientific research and post-marketing clinical experiences reported in peer review journals. Yet there seems limited understanding about its unique clinical implication associated with newly discovered molecular mechanism (traits) of BK channel activation. Hence this review article is using a focal lens with an eye on B-K channel activation to further delineate possible roles of rescula in modulating chronic parainflammation in the eye, which may eventually set it apart from the rest lipid hypotensive drugs such as latanoprost that is pro-inflammatory in nature. Cystoid macular edema and refractory glaucoma will be the key historical clinical case highlights.